Who is sponsoring NCT00260962?

NCT00260962 is sponsored by Ottawa Hospital Research Institute.

What condition does NCT00260962 study?

NCT00260962 studies Anorexia Nervosa.

What drugs are being tested in NCT00260962?

Interventions: Olanzapine, Day Hospital.

What is the status of NCT00260962?

NCT00260962 is currently COMPLETED.

Last reviewed 2018-01-05 · How we verify

Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study

NCT00260962 Phase 2 COMPLETED Results posted

The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.

Details

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 2
Status	COMPLETED
Enrolment	34
Start date	2000-09
Completion	2006-09

Conditions

Anorexia Nervosa

Interventions

Olanzapine
Day Hospital

Primary outcomes

Body Mass Index (BMI) (kg/m^2) — Baseline (week 2) and post-treatment (week 13)
Body Mass Index (BMI) measured in kg/m\^2 units. Measured at Baseline (week 2) and post-treatment (week 13).

Countries

Canada